A cost-utility analysis of BRCA1 and BRCA2 testing in high-risk breast cancer patients and family members in Thailand: a cost-effective policy in resource-limited settings
Breast cancer is a significant concern worldwide, and its impact on the well-being of Thai women is profound. The economic weight is evident, with treatment costs ranging from 966,306 to 1,510,886 Thai Baht throughout a lifetime.
Individuals carrying a mutation in BRCA1 or BRCA2 genes face an 80% chance of developing breast cancer and a 15-40% chance of ovarian cancer.
🧬 Opting for the BRCA gene test can be a strategic investment, even though it comes with a cost. This test for women at high risk of breast cancer proves cost-effective, identifying threats early and enabling proactive measures rather than dealing with the aftermath of developed cancer.
Recently, the National Health Security Office (NHSO) has pioneered a groundbreaking policy, positioning Thailand as the FIRST and ONLY country in ASEAN where people can access this test without charge!
Learn more about this impactful policy: Cost-Utility Analysis of BRCA1 and BRCA2 Testing in High-Risk Breast Cancer Patients and Family Members in Thailand.
